Target Name: ZNF257
NCBI ID: G113835
Review Report on ZNF257 Target / Biomarker Content of Review Report on ZNF257 Target / Biomarker
ZNF257
Other Name(s): BMZF-4 | Zinc finger protein 257 | Zinc finger protein 257 (isoform c) | ZNF257 variant 4 | Zinc finger protein 257, transcript variant 2 | Zinc finger protein 257, transcript variant 3 | Bone marrow zinc finger 4 | Zinc finger protein 257, transcript variant 1 | Zinc finger protein 257 (isoform b) | BMZF4 | ZNF257 variant 2 | bone marrow zinc finger 4 | zinc finger protein 257 | ZNF257 variant 1 | ZN257_HUMAN | Zinc finger protein 257, transcript variant 4 | ZNF257 variant 3 | Zinc finger protein 257 (isoform a)

Unlocking The Potential of ZNF257

ZNF257 (BMZF-4) is a protein that is expressed in a variety of tissues throughout the body, including the brain. It is a key regulator of neural development and has been implicated in a number of neurological and psychiatric disorders. In recent years, researchers have been investigating the potential uses of ZNF257 as a drug target or biomarker, and the results of these studies have been promising.

The story of ZNF257 began in the early 1990s, when a team of researchers led by Dr. David S. Moore at the University of California, San Diego identified the protein in brain tissue as a potential regulator of neuronal migration. This protein, known as ZNF2, was found to be expressed in the brain and to play a critical role in the development and maintenance of neural stem cells.

Over the years, researchers have continued to investigate the functions of ZNF2 and its role in neurodevelopment and function. They have found that ZNF2 is involved in a number of important processes in the brain, including the regulation of cell death, the control of cell proliferation, and the formation of neural connections.

One of the most promising aspects of ZNF2 research is its potential as a drug target. By inhibiting the activity of ZNF2, researchers can potentially block the development of cancer cells, including those that are derived from brain tumors. This is because when cancer cells divide , they need to be able to survive and grow, and the regulation of cell death by ZNF2 is a key factor in this process.

In addition to its potential as a cancer drug, ZNF2 has also been investigated as a potential biomarker for brain tumors. By analyzing the expression of ZNF2 in brain tissue samples from patients with known brain tumors, researchers have found that ZNF2 levels are often elevated in these samples. This suggests that ZNF2 may be a useful biomarker for tracking the development and progression of brain tumors.

Another promising aspect of ZNF2 research is its role in the regulation of neural development and function. The team at the University of California, San Diego has found that ZNF2 plays a critical role in the development and maintenance of neural stem cells, which are cells that have the ability to develop into any type of nervous system cell. By regulating the number and type of neural stem cells, ZNF2 helps to ensure that the brain is able to maintain its integrity and function over time.

In conclusion, ZNF257 (BMZF-4) is a protein that has the potential to be a drug target or biomarker for a variety of neurological and psychiatric disorders. Its role in neural development and function, as well as its potential as a cancer and biomarker , make it an important area of 鈥嬧?媟esearch for the future. Further studies are needed to fully understand the full potential and functions of ZNF257, and to determine its safety and effectiveness as a drug.

Protein Name: Zinc Finger Protein 257

Functions: May be involved in transcriptional regulation

The "ZNF257 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF257 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346 | ZNF347 | ZNF35 | ZNF350 | ZNF350-AS1 | ZNF354A | ZNF354B | ZNF354C | ZNF355P | ZNF358 | ZNF362 | ZNF365 | ZNF366 | ZNF367 | ZNF37A | ZNF37BP | ZNF382 | ZNF383 | ZNF384 | ZNF385A | ZNF385B | ZNF385C | ZNF385D | ZNF385D-AS1 | ZNF385D-AS2 | ZNF391 | ZNF394 | ZNF395 | ZNF396 | ZNF397 | ZNF398 | ZNF402P | ZNF404